1-3 of 3
Hosein Kouros-Mehr
Close
Sort by
Journal Articles

Phase 1 Study of SC291, a Hypoimmune, Allogeneic CD19-Directed CAR T Cell Therapy for Relapsed/Refractory B-Cell Malignancies (ARDENT) - Initial Clinical Data

Sattva S. Neelapu, L. Elizabeth Budde, Joseph P McGuirk, Saurabh Dahiya, Abhinav Deol, Philip A. Thompson, Nitin Jain, Matthew A Lunning, Xiaomeng Hu, Boris Gorovits, Danielle Quarles, Barbara Metallo, Meghan Flaherty, Weidong Zhang, Hosein Kouros-Mehr, Terry J. Fry, Sonja Schrepfer
Journal: Blood
Blood (2023) 142 (Supplement 1): 6852.
https://doi.org/10.1182/blood-2023-179441
Published: 2023
Journal Articles

Feasibility of Extracorporeal Delivery of Fusosomes to Generate CAR T Cells In Vivo

Jesse Green, Andrew Tucker, Aesha Vakil, Matt Scott-Skandera, Vasily Vagin, Dharmesh Dingar, Tarik Elgendi, Christina Proano, Brian Dolinski, Matthew A Lunning, Scott A Koepsell, Charles A Branson, Kerrie Enger, Danielle Quarles, Hosein Kouros-Mehr, Sarah Miller, Misha Shamashkin, Kutlu G Elpek
Journal: Blood
Blood (2023) 142 (Supplement 1): 3631.
https://doi.org/10.1182/blood-2023-186317
Published: 2023
Journal Articles

Identification of Healthy Donor Phenotypic and Functional Signatures That Predict Allogeneic, Hypoimmune CD19-Directed CAR T Cell Potency

Darin Salloum, Kavita Tundwal, Kwang Bom Choi, Ashley Ranere, Jaclyn Lock, Ben Lam, Jasmin Kristianto, John Yu, Jessica Li, John Lam, Pascal Beauchesne, Allison O'Rourke, Ouwen Liang, Aaron Lampano, Neal van Hoeven, Hosein Kouros-Mehr, Dave Shivak, Weidong Zhang, Tiffany Wan, Lisa Arjes, Christina Chaivorapol, Athena Wong, Adam Johnson, Paul Brunetta, Terry Fry
Journal: Blood
Blood (2023) 142 (Supplement 1): 6810.
https://doi.org/10.1182/blood-2023-188264
Published: 2023